AbCellera (ABCL) director lifts stake to 251K shares in latest insider buy

Rhea-AI Filing Summary

AbCellera Biologics Inc. (ABCL) director John S. Montalbano reported purchasing 10,000 Common Shares on 2026-08-18 at $11.03 per share in an open-market or private transaction. After this purchase, he directly holds 251,000 Common Shares, and there is an additional 5,000 Common Shares reported as indirectly owned by his spouse. The filing indicates these transactions were not reported under a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Buyer: 10,000 shares

Net Buy 2 txns

Insider Montalbano John S.

Role Director

Bought 10,000 shs ($110K)

Type	Security	Shares	Price	Value
Purchase	Common Shares	10,000	$11.03	$110K
holding	Common Shares	--	--	--

Holdings After Transaction: Common Shares — 251,000 shares (Direct); Common Shares — 5,000 shares (Indirect, By Spouse)

Key Figures

Shares Purchased: 10,000 Common Shares Purchase Price: $11.03 per share Direct Holdings After Transaction: 251,000 Common Shares +2 more

5 metrics

Shares Purchased 10,000 Common Shares Purchase on 2026-08-18 by director John S. Montalbano

Purchase Price $11.03 per share Price for 10,000 Common Shares bought on 2026-08-18

Direct Holdings After Transaction 251,000 Common Shares Direct ownership following reported purchase

Indirect Holdings By Spouse 5,000 Common Shares Indirect ownership reported as held by spouse

Net Buy/Sell Shares 10,000 shares (net buy) Net result of reported non-derivative transactions

Key Terms

indirect ownership, Rule 10b5-1 trading plan, open-market or private transaction

3 terms

indirect ownership financial

"there is an additional 5,000 Common Shares reported as indirectly owned by his spouse"

Rule 10b5-1 trading plan regulatory

"The filing indicates these transactions were not reported under a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market or private transaction financial

"at $11.03 per share in an open-market or private transaction"

FAQ

What insider transaction did ABCL director John S. Montalbano report on this Form 4?

Director John S. Montalbano reported purchasing 10,000 AbCellera (ABCL) Common Shares on 2026-08-18. The shares were bought in an open-market or private transaction at a price of $11.03 per share, increasing his directly held position.

At what price did John S. Montalbano buy AbCellera (ABCL) shares?

He purchased the AbCellera (ABCL) shares at $11.03 per share. The transaction involved 10,000 Common Shares on 2026-08-18, classified as a purchase in an open-market or private transaction, as reported in the Form 4 filing.

How many AbCellera (ABCL) shares does John S. Montalbano own after this transaction?

After the transaction, he directly owns 251,000 Common Shares of AbCellera (ABCL). The Form 4 also reports an additional 5,000 Common Shares held indirectly by his spouse, which are listed as indirect ownership in the filing.

Are any of John S. Montalbano’s AbCellera (ABCL) holdings reported as indirectly owned?

Yes. The Form 4 lists 5,000 AbCellera (ABCL) Common Shares as held indirectly "By Spouse". These are separate from his 251,000 Common Shares held directly following the reported purchase on 2026-08-18.

Was John S. Montalbano’s AbCellera (ABCL) share purchase made under a Rule 10b5-1 plan?

No. The Form 4 indicates the Rule 10b5-1 checkbox is not affirmed, meaning the reported AbCellera (ABCL) purchase of 10,000 shares at $11.03 was not disclosed as being under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/18/2026 - 02:45 PM Accepted by SEC EDGAR 08/18/2026 - 02:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Montalbano John S.

(Last) (First) (Middle)

C/O ABCELLERA BIOLOGICS INC

150 W 4TH AVENUE

(Street)

VANCOUVER

(City) (State) (Zip)

BRITISH COLUMBIA, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
AbCellera Biologics Inc. [ ABCL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/18/2026		P	V	10,000	A	$11.03	251,000	D
Common Shares								5,000	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	Tryn Stimart, attorney-in-fact	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)